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Tissue engineering in hair regrowth aims to develop innovative and not-invasive procedures to advance the hair regrowth. A placebo-
controlled, randomized, evaluator-blinded, half-head group study to compare hair regrowth with micrografts containing human hair
follicle mesenchymal stem cells (HF-MSCs) vs. placebo was reported. After 58 weeks, 27 patients displayed in the targeted area an
increase of hair count and hair density, respectively, of 18.0 hairs per 0.65 cm2 and 23.3 hairs per cm2 compared with baseline, while the
control area displayed a mean decrease of 1.1 hairs per 0.65 cm2 and 0.7 hairs per cm2 (control vs. treatment: P< 0.0001). After 26
months, 6 patients revealed dynamic hair loss and were retreated. More broad controlled examinations are required. HF-MSCs
contained in micrografts may represent a safe and viable treatment alternative against hair loss.
1. Introduction
For therapeutic hair regrowth, the use of micrografts con-
taining autologous human hair follicle mesenchymal stem
cells (HF-MSCs) has not been adequately considered. An-
drogenetic alopecia (AGA) is a typical, chronic hair loss
disorder, described by dynamic hair loss, experienced in-
terestingly by 80% of white men and 40% of ladies [1–3].
Medications and treatments affirmed for AGA are minox-
idil, finasteride, and hair transplant [2]. +e effect of au-
tologous platelet-rich plasma (A-PRP) has been exhibited
[3, 4]. In AGA, the miniaturization of the follicles is de-
termined by diminishment of anagen and with an im-
provement in the percentage of resting hair follicles (HFs),
telogen, containing microscopic hairs in a hairless scalp [5].
Moreover, invading lymphocytes and mast cells have been
seen around the miniaturizing follicle [6], detailed in the
stem cell-rich lump zone [7].
In hair loss scalp, hair follicle stem cell numbers stay
unaltered, though the number of more actively proliferating
progenitor cells particularly diminishes [8]. +is proposes
going bald scalp either does not have an activator or has an
inhibitor of hair follicle (HF) growth.
In a previous study [9], the authors showed the use of
autologous micrografts, reporting mechanical detachment
of human hair follicle stem cells (HFSCs) is not expanded by
a slow centrifugation according to minimal manipulation
rules.
Right now, the authors intend to clarify the clinical and
trichoscopic effects of micrograft scalp infusion in people
affected by AGA.
Additionally, patients’ fulfillment and computerized
trichogram examination have affirmed the quality of the
outcomes.
1.1. Scope of the paper. +e objective of the present work is to
evaluate the hair regrowth obtained by micrograft injections.
+e authors report here the long-term clinical efficacy of
micrograft injections and compare also the results obtained
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with placebo. +is report would also provide a concise re-
view of recent advances in this field.
2. Methods
2.1. Study Overview. +e primary outcome for the placebo-
controlled, randomized, evaluator-blinded, half-head group
study was to compare long-term results in hair regrowth
with composite micrografts enriched with HF-MSCs vs.
placebo (saline solution). +e secondary outcome was to
confirm through histological evaluation the follicle quantity,
safety, and feasibility in HF-MSC-treated skin biopsies.
Evaluation of trichograms was performed by medical doc-
tors blinded to the procedure. AGA diagnoses were estab-
lished by performing detailed therapeutic history, clinical
examination, blood test, urinalysis, and trichoscopic
highlights.
+e grade of AGA in the selected patients was estimated
according to the Norwood–Hamilton (NH) and Ludwig (L)
scales.
2.2. Patients. +is investigation enlisted 27 patients, of
whom 17males showed AGA grades 2–5 as controlled by the
NH scale and 10 females showed AGA grades 1-2 as dictated
by the L scale. Fundamental exclusion criteria included
immunosuppression and cancer, sepsis, and the utilization
of pharmacological therapeutics targeting on AGA (finas-
teride, similar drugs, and/or antiandrogens) in the earlier
year. Localized exclusion criteria included the utilization of
topical medicines for AGA (lotions as minoxidil, prosta-
glandin analogs, retinoids, or corticosteroids) in the earlier
year.
2.3.MicrograftProcedure. Autologous micrografts of HFSCs
were prepared using the “Gentile protocol” (Figures 1(a)–
1(d) and 2(a)–2(d)), modifying and improving the proce-
dure published previously [9]. In brief, this procedure
represents an innovative clinical approach to obtain au-
tologous micrografts through a mechanical fragmentation of
different biological tissues (epidermis, dermal, fat tissue,
hair, bulb area, and bulge area) and requires different steps
of execution. +e first step is harvesting of the scalp tissues
(30–50 fragments depending on the size of the area to treat)
with punch biopsy (2mm diameter) (Figure 1(a)), storing in
saline solution (Figure 1(b)), and cutting the fragments into
strips of 2.0× 2.0mm (Figure 1(c)), resulting in collection
and disaggregation of the strips (group of 3 fragments each
time) sterilely through a manual splitting performed by
multiple incisions with scalpel number 11 (Figure 1(c)) in
1.2mL of saline (NaCl 0.9%) for each 3 fragments with the
aim of sorting a cell group having a diameter of 80–120 μm.
+e second step is collecting the suspension obtained; an
average 20ml for 50 fragments was disaggregated and
fragmented (Figures 1(d) and 2(a)), in two 10mL Luer-Lock
syringes, and centrifuged for 3 minutes at 3000RPM
(Figure 2(b)); 1.5mL of the supernatant was removed from
each syringe, and 9ml of the micrograft’s suspension was
obtained; two syringes containing 4.5ml of the micrograft’s
suspension were positioned in a mesotherapy gun
(Figure 2(c)). +e third step is mechanical and controlled
infiltration, using 10ml syringes in the selected area of the
scalp through a medical device, a mesotherapy gun,
equipped with software that allows to schedule the depth of
injection and the amount of infiltration per cm2, with the
same angle of inclination (Figure 2(d)).
2.4. Protocol and Injection of the Micrograft’s Suspension.
+e scalp was divided into six different anatomical areas
(left frontal area, right frontal area, left parietal area, right
parietal area, left vertex area, and right vertex area); an-
esthesia (local or potentially fundamental) was not per-
formed. +e micrograft’s suspension interfollicular
infusions (0.2 mL/cm2) were performed to the targeted
area (TA) at 5mm depth utilizing a mesotherapy medical
device outfitted with a 10mL Luer-Lock syringe (Sup-
plemental Material) with a 30-gauge needle, in three
sessions spaced 45 days apart. +e micrograft’s suspension
infusions were conveyed to the frontal scalp, while placebo
infusions (saline solution NaCl 0.9%) were infused in the
parietal areas in patients with thinning confined to the
frontal and parietal areas. In a similar manner, for thinning
restricted to the parietal and vertex regions, micrografts’
suspension was infused in the parietal area, and placebo
was infused in the vertex area. Specifically, to better show
the clinical impacts, we partitioned every area into two
sides and performed the infusions in a chosen side (left or
right) (Supplemental Material). Equivalent quantities of
the autologous micrograft’s suspension and placebo in-
fusions were made.
2.5. Clinical Evaluation of Hair Growth. Assessment of hair
growth (HG) was in different weeks (Ws) after the treat-
ment, summarized into four phases: T0 (Figures 3(a) and
3(b)), before the first infusion (Figures 4(a) and 5(a)); T1-
3Ws and T2-9Ws after the last treatment (Figure 4(b)); T3-
16Ws and T4-23Ws after the last treatment (Figure 4(c));
and T5-58Ws after the last treatment (Figures 3(c), 3(d),
4(d), and 5(b).
+e impacts of micrografts’ suspension and placebo
medications on HG were evaluated using photography
(same position, same contrast, and same light), the physi-
cian’s and the patient’s global evaluation scale, and stan-
dardized phototrichograms.
2.6. Trichoscopic Evaluation of Hair Growth. In all partici-
pants, two translational regions of thinning, one at the fringe
of the treatment half and the other at a moment along the
outskirt of the placebo half, have been marked with a
semipermanent tattoo for the subsequent trichogram.
Phototrichograms (Figures 3(a)–3(d)) were performed
in all TA using FotoFinder video epiluminescence systems in
combination with the TrichoScan digital image analysis.
TrichoScan was performed to evaluate hairs per 0.65 cm2
described as hair count (HC), hairs per cm2 described as hair
density (HD), hair thickness (HT), anagen-to-telogen ratio,
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and vellus hair-to-terminal hair ratio. All hairs with a
thickness >40 μm are categorized as terminal hairs, while
those with lesser diameter are categorized as vellus hairs.
2.7. Immunocytochemistry and Cytospin. Micrografts’ sus-
pension tests (n� 27) were fixed with 4% paraformaldehyde
and characterized for mesenchymal CD44 [10] and epithelial
Figure 1: Micrograft’s preparation with the “Gentile protocol” (first and second steps). (a) Harvesting of the scalp tissues with punch biopsy
(2mm diameter). (b) Storing scalp tissues in saline solution. (c) Cutting and splitting of the fragments into strips of 2.0× 2.0mm (group of 3
fragments each time) sterilely through amanual splitting performed bymultiple incisions with scalpel number 11 in 1.2mL of saline for each
3 fragments. (d) Splitted strips and obtained suspension; an average 20ml for 50 fragments was disaggregated and fragmented.
Figure 2: Micrograft’s preparation with the “Gentile protocol” (third step). (a) 20ml of suspension containing strips splitted. (b) Collection
of the suspension obtained, in two 10mL Luer-Lock syringes, and centrifugation for 3 minutes at 3000 RPM. (c) Two syringes containing
4.5ml of the micrograft’s suspension were positioned in a mesotherapy gun. (d) Mechanical and controlled infiltration, using 10ml syringes
in the selected area of the scalp through a mesotherapy gun.
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CD200 [11] stem cell markers, according to previously re-
ported studies [10, 11]. After cytospin, cells were analyzed by
immunocytochemistry with specific primary antibodies
(CD200 ab203887, 1 :100; CD44 sc-9960, 1 :10). Positive
cells were counted in the total area (as percentage of positive
cells/total cell number) under a light microscope at 400x
magnification (Eclipse E600, Nikon, Japan), and micro-
photographs were captured by a DXM1200F digital camera
(Nikon) using ACT-1 software (Nikon).
2.8. StatisticalAnalysis. HD andHCwere expressed as mean
plus or minus standard deviation (SD). HD and HC dif-
ferences between the different time points were evaluated by
one-way repeated-measures analysis of variance; post hoc
analysis was performed using the Sidak test. All tests were 2-
tailed, and P< 0.05 was considered statistically significant.
3. Results
3.1. Long-Term Clinical and Trichoscopic Results. +e results
obtained displayed an improvement in the mean HC at T5
after 58 weeks (58 weeks vs. 0 weeks) of 18.0 hairs in the TA
(Figures 3(c) and 3(d)) compared with baseline (Figures 3(a)
and 3(b)), while the control area (CA) displayed a mean
decrease of 1.1 hairs (control vs. treatment: P< 0.0001).
Accordingly, a mean increase in the total HD of 23.3 hairs
per cm2 (Figures 3(c) and 3(d)) compared with baseline
(Figures 3(a), 3(b), 4(a), and 5(a)) was observed at T5
(Figures 4(d) and 5(b)), and the CA displayed a mean de-
crease of 0.7 hairs per cm2 (control vs. treatment:
P< 0.0001).+ere were no statistically significant differences
in vellus HD between the TA and the CA at T5. After 26
months, 6 patients detailed dynamic hair loss. +ose six
patients were retreated.
Figure 3: TrichoScan analysis performed by FotoFinder in a 41-year-old male with AGA who is nonsmoker; he is at stage 3 vertex balding
according to the NH scale, as shown in Figure 4. (a, b) At T0, preoperative HC was 72.2 hairs per 0.65 cm2, HD was 97.5 hairs per cm2, and
proportions of anagen and telogen hairs were 59.0% and 41.4%, respectively. (c, d) At T5, postoperative HC was 90.5 hairs per 0.65 cm2, HD
was 122.8 hairs per cm2, and proportions of anagen and telogen hairs were 48.6% and 51.7%, respectively.
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Figure 4: A 38-year-old female with AGA who is nonsmoker and classified to have stage 2 vertex balding according to the L scale. (a)
Preoperative image at T0 with thinning localized to the frontal and parietal areas. (b) Postoperative image at T2 (9Ws after the last
treatment); the arrow indicates the left parietal area treated with two micrograft injections with the increase of HD vs. the right parietal area
treated with placebo. (c) Postoperative image at T4 (23Ws after the last treatment); the arrow indicates again the same area with the increase
of HD. (d) Postoperative image at T5 (58Ws after the last treatment); the arrow indicates the final result obtained.
Figure 5: A 41-year-old male with AGA who is nonsmoker and classified to have stage 3 vertex balding according to the NH scale. (a)
Preoperative image at T0 with thinning localized to the vertex, parietal, temporal, and frontal areas. (b) Postoperative situation of the scalp at
T5-58Ws after the last treatment with the arrow indicating improvement of HD in the right vertex area treated with two micrograft
injections vs. baseline situation in the same area and vs. the left vertex area treated with placebo.
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3.2. Immunophenotypic Identification and Cell Counting.
Twenty-seven samples of the micrograft’s suspension were
cultured and subsequently characterized by cytospin and
immunocytochemistry to identify the HFSCs. +e authors
considered the cellular population containing HF-MSCs
and human hair follicle epithelial stem cells (HF-ESCs) as
HFSCs.
From cell counting, each scalp tissue suspension con-
tained a mean of about 4123.7± 581.8 cells. In particular, the
percentage of CD44+ HF-MSCs (from the dermal papilla)
(Figure 6(a)) was about 4.6%± 0.65%, whereas the per-
centage of CD200+ HF-ESCs (from the bulge area)
(Figure 6(b)) was 2.4%± 0.4%. +e remaining cells were
S100A4+ dermal fibroblasts (>87%) and epidermal cells
(epithelial cells and melanocytes< 12%).
4. Discussion
Current medications for AGA with the approval of the US
Food and Drug Administration (FDA) include minoxidil
and finasteride.
Minoxidil (pyrimidine derivate) lotion 2% was the first
drug with FDA approval for treatment of AGA in males
(1988) and females (1991) [12, 13]. Minoxidil as 5% lotion
was approved in 1997 for AGA in males and as 5% foam in
2006 [12, 13]. Minoxidil extends the anagen period and
increases HF diameter through activation of prostaglandin-
endoperoxide synthase-1, which increases the level of
prostaglandin E2 [12]. Minoxidil improves the survival of
dermal papilla cells (DPCs) by activating ERK and Akt and
by increasing the Bcl-2/Bax ratio [13].
Finasteride is a type II 5-alpha-reductase inhibitor which
decreases dihydrotestosterone (DHT) by about 65% in se-
rum, prostate, and scalp. It was registered in Europe in 1992
for treatment of benign prostatic hyperplasia [14, 15]. +e
drug became registered in the United States of America
(1993) and Europe (1994) for AGA therapy (mild to mod-
erate) in male patients [14, 15]. Oral finasteride also prolongs
the hairs’ anagen phase, with the gradual improvement of
hair thickness [14]. Finasteride reduces the thinning, in-
creasing the expression of caspase and apoptosis inhibitors,
stimulating the anagen phase resulting in HG [15, 16].
Alternative treatments, based on autologous sources and
minimal invasive approach, are represented byA-PRP and adult
stem cells (SCs) as adipose-derived mesenchymal stem cells
(AD-MSCs) and HFSCs [17]. A more invasive surgical ap-
proach was limited to hair transplant indicated only for patients
affected by aggressive conditions of AGA and hair loss [17].
+e clinical effectiveness of A-PRP as AGA therapy was
reported in recent reports [3, 4, 17]. In this case, HG would
be stimulated by antiapoptotic effects of A-PRP through the
activation of the Bcl-2 protein (antiapoptotic regulator) and
Akt signaling, prolonging the survival of DPCs during the
hair cycle [3, 4, 17]. +e upregulation of fibroblast growth
factor-7 (FGF-7)/β-catenin signaling pathways with A-PRP
was suggested to stimulate HG by inducing HFSC differ-
entiation as well as prolonging the anagen phase of the HG
cycle [3, 4, 17]. It also improved the perifollicular vascular
plexus through the increase of vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF)
levels, which have the angiogenic potential [3, 4, 17].
Adil and Godwin [18] reported selecting trials, based on the
US Preventive Services Task Force quality assessment process,
conducted separately for 5 groups of studies, in which the
authors analyzed low-level laser light therapy, 5%minoxidil, 2%
minoxidil, and 1mg finasteride in male patients and 2% mi-
noxidil in females. All the procedures were more effective
compared to placebo (P< 0.00001), in the 5 meta-analyses.
To better explain the clinical results obtained by the use
of minoxidil, finasteride, A-PRP, and HFSCs, it is necessary
to report the most recent outcomes in hair density and hair
count obtained for these treatments. In detail, in a recent
study of Gentile et al. [19], hair density improvement for
A-PRP 23 weeks after the third infiltration (one infiltration
was performed three times for 30 days each) was 28± 2%
hairs/cm2 compared with placebo (saline solution). In the
same study, hair density improvement for HFSC treatment
23 weeks after the second infiltration (one infiltration was
performed every 60 days for two times) was 29± 5% hairs/
cm2 compared with placebo (saline solution) [19]. In a study
of Van Nestle et al. [20], 212 males affected by AGA were
selected in a randomized model to receive 1mg finasteride
daily (study group) or placebo (control group) for 48Ws. At
48Ws, the study group had a net improvement compared
with the control group in total and anagen HCs of 17.3± 2.5
hairs (8.3%± 1.4%) and 27.0± 2.9 hairs (26%± 3.1%), re-
spectively (P< 0.001).
In a recent study of Bao et al. [21], regarding the use of
5% minoxidil, the increase in HD 24Ws after the treatment
was 18.8 hairs/cm2 in the group of patients treated with
topical application and 38.3 hairs/cm2 in the group of pa-
tients treated with electrodynamic microneedling with
topical 5% minoxidil [21].
Regarding the effectiveness/expenses balance, it is pos-
sible to affirm that the drugs discussed could be effective in
AGA patients but cause a dependence promoted by the need
to take finasteride daily or apply minoxidil topically for
12–24 months according to the analyzed studies [20, 21].
On the contrary, the use of autologous therapies can free the
patient from the daily routine, but the greater invasiveness of the
procedures can lead the patient to be less compliant.
Adult SCs can be harvested, prevalently, from two tis-
sues, represented by fat tissue (FT) and scalp tissue (ST).+e
FT contains a great number of mesenchymal stem cells
(MSCs) with multilineage separation potential. +e FTcould
be collected using a minimally aggressive procedure as a
gentle liposuction, and it must be identified as a substitute to
the bone marrow (BM) for surgical applications because it is
gifted on high frequency of AD-MSCs [17].
AD-MSCs and stromal vascular fraction cells (SVFs) are
vital for the ignition of epidermal SCs in the scalp, which are
activated by the release of growth factors (GFs). +e VEGF
drives HG and the extension of the HFs measured by ac-
tivation of angiogenesis. +e PDGF prompts the anagen
stage, and insulin-like growth factor-1 (IGF-1) controls the
HG cycle [17]. Another action is the implementation of
angiogenesis and improvement of the blood supply to DPCs.
In addition, they have immunomodulatory and
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immunosuppressive activity through the release of leuke-
mia-inhibiting factor (LIF), kynurenine, and prostaglandin
E2 (PGE2) [17]. +e paracrine activity of AD-MSCs and
SVFs is based on TB4, EGR-1, SDF-1, and MCP-1 with
implication of humanHFs [17]. TB4 allows for the activation
of SCs in HFs, increasing their relocation into the follicle and
splitting. SDF-1 improves the cell tropism toward the follicle
and increases the angiogenesis, through an activation im-
provement of EGR-1 [17]. MCP-1, despite having inflam-
matory capacity, has demonstrated a tissue regenerative
effect [17].
It is likely that the anti-inflammatory and immuno-
modulatory properties of PRP or dermal and progenitor
stem cells may favor hair regrowth [22–24] since AGA, as
known, is characterized by an inflammatory infiltrate, re-
sponsible for the inflammatory cytokine release [22].
Stoll et al. [25] suggested in a preclinical model that trauma
of the skin produced by microneedling injections would in-
duce long-term hair regrowth. In this study, five Ws after
microneedling injections, hair regrowth started, followed by a
hyperpigmentation reduction. 12Ws later, a 90% improve-
ment in coat coverage was reported at previously thinning
areas. 12 months later, coat conditions remained stable [25].
As reported by Fertig et al. [26], the microneedling
injection is not an aggressive treatment based on a simple
procedure where small needles are rolled over the epidermis,
stimulating collagen production, angiogenesis, and growth
factor release. +e microneedling procedure has been tested
in a great range of dermatologic pathologies as alopecia
areata and AGA [26].
For ST, in previous research conducted by Gentile et al.
[9], a procedure was tuned to collect HFSCs with minimal
manipulation based on the centrifugation of the scalp’s
fragments obtained by punch biopsy, without cellular ex-
tension or culture. In this procedure, we succeeded in cell
counting and identifying CD44+ HF-MSCs and CD200+
HF-ESCs, according to previously reported studies [10, 11].
In patients affected by AGA with scalp presenting hair
loss, the HFSC numbers were reported to stay invariant [8].
However, the reconstitution of a completely sorted-out
and utilitarian HF from separated cells seeded in culture is a
test as yet pending in regenerative medicine [27].
HFs contain a niche for grown-up stem cells represented by
the lump, containing epithelial andmelanocytic stem cells [28].
SCs in the hair lump, a differentiated structure inside the
lower permanent portion of HFs, can create the inter-
follicular epidermis, sebaceous glands, and HF framework
[29, 30].
+e lump ESCs can reconstitute in a simulated in vivo
framework similarly to a new HF [31, 32].
Yu et al. [28] demonstrated that human HFs contain a
stem cell populace that may be separated into the smooth
muscle cell, neuron, and melanocyte heredities in the in-
duction medium. +eir information demonstrates that
Oct4-positive cells are available in the human epidermis, and
the majority of them are situated in the HFs in vivo. Oct4 has
a place in the family of POU-domain transcription factors
that are communicated in pluripotent cells of the developing
embryo and mediate pluripotency [33]. Each mature HF is a
regenerating framework, which physiologically experiences
cycles of growth (anagen), relapse (catagen), and rest (tel-
ogen) at various times in a grown-up’s life [34]. In catagen,
HFSCs are kept up in the lump. At this point, the resting
follicle reenters anagen (regeneration) when legitimate
molecular signals are given. Amid the late telogen to the
early anagen phase, signals from the dermal papilla (DP)
promote the hair germ and switch off lump stem cells to
wind up activated [35].
Numerous paracrine factors are engaged with this
crosstalk at various hair cycle stages, and some signaling
pathways have been implicated [36–38]. In anagen, SCs in
the lump offer ascent to hair germs; at this point, the
transient increasing cells in the grid of the new follicle
proliferate quickly to frame another hair filament [39].
At this point, it appears necessary to better know in
which stage it is necessary to act. Regeneration of HFs was
likewise seen in people [40] when dermal sheath tissue was
utilized, which was adequate to regenerate additionally the
DP structure. After implantation, the whisker DP was
equipped for promoting HF regeneration holding the data to
decide the hair fiber type and follicle size [41]. Grafting of
dermal-inductive tissue was restricted by the way that it was
impractical to produce more HFs than the one obtained
from the donor tissues. To defeat this constraint, diverse
Figure 6: Immunophenotypic analysis of HFSCs in human scalp biopsy. Immunocytochemistry for CD44 and CD200 stem cell markers. (a)
HF-MSCs. (b) HF-ESCs. Scale bar� 25 μm.
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methodologies and exploratory models utilizing freshly or
cultured isolated cells from both dermal and dermal/epi-
dermal origin were tried. +e vast majority of them included
neonatal and embryonic murine cells.
Balañá et al. [27] in a preclinical model created a epi-
dermal-dermal skin substitute by seeding cultured human-
derived HF-ESCs and DPCs, in an acellular dermal grid.+is
product was grafted into a wound produced on bare mice
skin, and fourteen days later, in the treated area, histological
structures reminiscent of a great range of phases of em-
bryonic HF improvement were identified, demonstrating
concentric cellular layers of human origin and expressing
k6hf, keratin in epithelial cells of the companion layer. +e
results obtained suggested that both epithelial and dermal
cultured cells from the grown-up human scalp in a dermal
scaffold could create in vivo structures that reiterate em-
bryonic hair improvement.
Kalabusheva et al. [42] aimed to build up a simulated HF
germ, through combining postnatal human DPCs and skin
epidermal keratinocytes (KCs) in a hanging drop culture.
Blended HF germ-like structures showed the start of the
epithelial-mesenchymal collaboration, including WNT
pathway enactment and expression of follicular markers.
+e impact of DP cell niche components including dis-
solvable components and extracellular matrix (ECM) mol-
ecules was examined during the time spent on the organoid
assembling and growth.+e outcomes obtained showed that
soluble components had little impact on HF germ genera-
tion and Ki67+ cell score inside the organoids although
BMP6 and VD3 kept up effectively the DP character in the
monolayer culture. Talavera-Adame et al. [43] revealed the
biomolecular pathway involved in cellular therapy.
Specifically, it has been additionally demonstrated that
Wnt/β-catenin signaling is necessary for the growth and
upkeep of DPCs [44, 45]. +e increment of Wnt signaling in
DPCs is one of the principal factors that enhance HG [44].
Festa et al. [46] detailed that adipocyte progenitor cells
bolster the SC niche and help conduct the complexHG cycle.
+is approach aimed to regenerate HFs which is fascinating
and raises the likelihood that one can conduct or reestablish
the hair cycle in the thinning by stimulating the niche with
autologous fat improved with stromal cells.
Along these lines, Perez-Meza et al. [47] detailed the
safety, tolerability, and in patients with hereditary thinning
treated with subcutaneous scalp infusion of advanced FT.
+e discoveries propose that scalp stem cell-enriched fat
grafting may represent a promising elective way for treating
hair loss in people.
Fukuoka and Suga [48] reported a mean increment of
29± 4.1 hairs in male patients and 15.6± 4.2 hairs in females
treated with fat-derived stem cell-conditioned medium
infusion.
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